BE2016C040I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2016C040I2 BE2016C040I2 BE2016C040C BE2016C040C BE2016C040I2 BE 2016C040 I2 BE2016C040 I2 BE 2016C040I2 BE 2016C040 C BE2016C040 C BE 2016C040C BE 2016C040 C BE2016C040 C BE 2016C040C BE 2016C040 I2 BE2016C040 I2 BE 2016C040I2
- Authority
- BE
- Belgium
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
- C08G65/48—Polymers modified by chemical after-treatment
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
- C08L71/02—Polyalkylene oxides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2203/00—Applications
- C08L2203/02—Applications for biomedical use
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Polyethers (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34991702P | 2002-01-18 | 2002-01-18 | |
| PCT/US2003/001559 WO2003061577A2 (en) | 2002-01-18 | 2003-01-17 | Polyalkylene glycol with moiety for conjugating biologically active compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE2016C040I2 true BE2016C040I2 (en) | 2022-05-17 |
Family
ID=27613339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2016C040C BE2016C040I2 (en) | 2002-01-18 | 2016-08-04 |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US8017733B2 (en) |
| EP (3) | EP1476181B1 (en) |
| JP (5) | JP2005526151A (en) |
| KR (1) | KR100964411B1 (en) |
| CN (2) | CN101700401B (en) |
| AU (1) | AU2003210564B2 (en) |
| BE (1) | BE2016C040I2 (en) |
| BG (1) | BG66525B1 (en) |
| BR (1) | BRPI0306993B8 (en) |
| CA (4) | CA2473526C (en) |
| CY (3) | CY1117349T1 (en) |
| CZ (1) | CZ2004877A3 (en) |
| DK (2) | DK3025726T3 (en) |
| EA (2) | EA009783B1 (en) |
| EE (1) | EE05509B1 (en) |
| ES (2) | ES2774801T3 (en) |
| FR (1) | FR16C0034I2 (en) |
| GE (2) | GEP20064024B (en) |
| HU (4) | HUE047557T2 (en) |
| IL (1) | IL163006A (en) |
| IS (1) | IS2989B (en) |
| LU (1) | LU93162I2 (en) |
| ME (2) | ME00239B (en) |
| MX (1) | MXPA04006855A (en) |
| NL (1) | NL300826I2 (en) |
| NO (4) | NO339857B1 (en) |
| NZ (1) | NZ534708A (en) |
| PL (2) | PL213322B1 (en) |
| PT (1) | PT3025726T (en) |
| RS (1) | RS55578B1 (en) |
| SI (2) | SI1476181T1 (en) |
| SK (1) | SK3102004A3 (en) |
| UA (1) | UA82184C2 (en) |
| WO (1) | WO2003061577A2 (en) |
| ZA (1) | ZA200406555B (en) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150246097A9 (en) * | 2002-01-18 | 2015-09-03 | Biogen Idec Ma Inc. | Polyalkylene Polymer Compounds and Uses Thereof |
| DK3025726T3 (en) * | 2002-01-18 | 2019-12-09 | Biogen Ma Inc | POLYALKYLENE POLYMER COMPOUNDS AND APPLICATIONS THEREOF |
| KR100974843B1 (en) | 2002-09-09 | 2010-08-11 | 넥타르 테라퓨틱스 | Water Soluble Polymer Alkanal |
| US8129330B2 (en) | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
| CN102319437B (en) * | 2002-12-26 | 2017-10-13 | 山景医药公司 | Polymer conjugates of interferon-beta with enhanced biological utility |
| AU2003303636B2 (en) * | 2002-12-26 | 2010-08-05 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
| US7432331B2 (en) | 2002-12-31 | 2008-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
| JP4490290B2 (en) | 2002-12-31 | 2010-06-23 | ネクター セラピューティクス アラバマ，コーポレイション | Hydrolytically stable maleimide terminated polymer |
| PT1635875E (en) | 2003-06-26 | 2008-12-09 | Psivida Inc | SYSTEM OF LIBERATION OF A DRUG WITH INITIAL GELIFICATION |
| DK1635787T3 (en) | 2003-06-26 | 2012-03-26 | Control Delivery Sys Inc | Bioerodible delayed release drug delivery systems |
| WO2005118537A2 (en) * | 2004-05-31 | 2005-12-15 | Ranbaxy Laboratories Limited | Arylpiperazine derivatives as adrenergic receptor antagonists |
| KR101320936B1 (en) | 2004-12-21 | 2013-10-23 | 넥타르 테라퓨틱스 | Stabilized polymeric thiol reagents |
| US20070004635A1 (en) * | 2005-06-02 | 2007-01-04 | Schering Corporation | Method of treating interferon non-responders using HCV protease inhibitor |
| CA2614200A1 (en) * | 2005-07-08 | 2007-01-18 | Elan Pharmaceuticals, Inc. | Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds |
| MX2008014520A (en) * | 2006-05-22 | 2008-11-27 | Elan Pharm Inc | Preparation of polymer conjugates of vla-4 antagonists via a mitsunobu' s reaction. |
| US20100222546A1 (en) * | 2006-11-28 | 2010-09-02 | David Crich | Methods for the preparation of functionalized peptides, proteins and carbohydrates and their conjugates |
| CA2693645A1 (en) * | 2007-07-11 | 2009-01-15 | Enzon Pharmaceuticals, Inc. | Polymeric drug delivery systems containing an aromatic allylic acid |
| EP2175878A4 (en) * | 2007-07-11 | 2014-12-03 | Belrose Pharma Inc | Polymeric drug delivery system containing a multi-substituted aromatic moiety |
| CL2008002399A1 (en) * | 2007-08-16 | 2009-01-02 | Pharmaessentia Corp | Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c. |
| AU2009255994B2 (en) * | 2008-06-05 | 2014-07-17 | Bristol-Myers Squibb Company | Use of pegylated Type III Interferons for the treatment of hepatitis C |
| TWI421093B (en) * | 2008-07-31 | 2014-01-01 | Pharmaessentia Corp | Peptide-polymer conjugates |
| GB0823309D0 (en) * | 2008-12-19 | 2009-01-28 | Univ Bath | Functionalising reagents and their uses |
| WO2010140350A1 (en) | 2009-06-02 | 2010-12-09 | パナソニック株式会社 | Down-mixing device, encoder, and method therefor |
| UA109646C2 (en) * | 2009-12-10 | 2015-09-25 | THERAPEUTIC APPLICATION OF POLYMER PROTEIN CONJUGATES | |
| US20130225789A1 (en) * | 2012-02-29 | 2013-08-29 | Yi Sun | Polyethylene Glycol Having Hetero Multiple Functional Groups |
| US8993614B2 (en) | 2012-03-15 | 2015-03-31 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
| KR101475630B1 (en) * | 2013-05-31 | 2014-12-22 | 동국대학교 산학협력단 | Composition for the prevention or treatment of Hepatitis C, comprising extracts or fractions of Vitidis Vinferae Radix as an effective ingredient |
| US11759500B2 (en) * | 2014-07-24 | 2023-09-19 | Abion Inc. | PEGylated interferon-beta variant |
| ES2824028T3 (en) * | 2014-08-19 | 2021-05-11 | Biogen Ma Inc | PEGylation method |
| GB201419108D0 (en) | 2014-10-27 | 2014-12-10 | Glythera Ltd | Materials and methods relating to linkers for use in antibody drug conjugates |
| CA2964390A1 (en) | 2014-11-06 | 2016-05-12 | Pharmaessentia Corporation | Dosage regimen for pegylated interferon |
| EP3421442B1 (en) * | 2017-06-28 | 2020-08-05 | Construction Research & Technology GmbH | Dispersant for inorganic particles |
| US11472894B2 (en) | 2018-07-23 | 2022-10-18 | Carnegie Mellon University | Enzyme-assisted ATRP procedures |
| US12053529B2 (en) | 2018-08-01 | 2024-08-06 | Carnegie Mellon University | Amino-reactive positively charged ATRP initiators that maintain their positive charge during synthesis of biomacro-initiators |
| CN109232898A (en) * | 2018-08-02 | 2019-01-18 | 张玲 | A kind of preparation method of the polyimides new material with anticoagulant functions |
| CN111534458B (en) * | 2020-04-13 | 2022-01-14 | 浙江工业大学 | Achromobacter TBC-1 and application thereof in degradation of 1,3,6,8-tetrabromocarbazole |
| CN113716982B (en) * | 2021-08-24 | 2022-05-06 | 重庆云瑞肥业有限公司 | Fermentation fertilizer making device for recycling food waste |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4002531A (en) * | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
| DE3262575D1 (en) | 1981-12-23 | 1985-04-18 | Schering Corp | Stabilised interferon formulations and their preparation |
| WO1985003934A1 (en) * | 1984-03-06 | 1985-09-12 | Takeda Chemical Industries, Ltd. | Chemically modified protein and process for its preparation |
| GB8334102D0 (en) * | 1983-12-21 | 1984-02-01 | Searle & Co | Interferons with cysteine pattern |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| DE3675588D1 (en) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE). |
| DE3676670D1 (en) | 1985-06-26 | 1991-02-07 | Cetus Corp | SOLUBILIZATION OF PROTEINS FOR PHARMACEUTICAL COMPOSITIONS BY POLYMER CONJUGATION. |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
| JP2514950B2 (en) * | 1986-03-10 | 1996-07-10 | エフ・ホフマン―ラ ロシユ アーゲー | Chemically modified protein, its production method and intermediate |
| US4894226A (en) * | 1986-11-14 | 1990-01-16 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polyproline conjugation |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US5135919A (en) | 1988-01-19 | 1992-08-04 | Children's Medical Center Corporation | Method and a pharmaceutical composition for the inhibition of angiogenesis |
| US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5286637A (en) * | 1989-08-07 | 1994-02-15 | Debiopharm, S.A. | Biologically active drug polymer derivatives and method for preparing same |
| US5252714A (en) * | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| US5595732A (en) * | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
| WO1993012145A1 (en) * | 1991-12-19 | 1993-06-24 | Baylor College Of Medicine | Pva or peg conjugates of peptides for epitope-specific immunosuppression |
| ZA933926B (en) * | 1992-06-17 | 1994-01-03 | Amgen Inc | Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules |
| US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| US5298410A (en) * | 1993-02-25 | 1994-03-29 | Sterling Winthrop Inc. | Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life |
| US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5681811A (en) * | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5874075A (en) * | 1993-10-06 | 1999-02-23 | Amgen Inc. | Stable protein: phospholipid compositions and methods |
| US5951974A (en) | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
| DE69430251T2 (en) * | 1993-11-10 | 2002-11-07 | Enzon, Inc. | IMPROVED INTERFERON POLYMER CONJUGATES |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US5639725A (en) | 1994-04-26 | 1997-06-17 | Children's Hospital Medical Center Corp. | Angiostatin protein |
| US5730990A (en) | 1994-06-24 | 1998-03-24 | Enzon, Inc. | Non-antigenic amine derived polymers and polymer conjugates |
| US5650234A (en) | 1994-09-09 | 1997-07-22 | Surface Engineering Technologies, Division Of Innerdyne, Inc. | Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US5738846A (en) * | 1994-11-10 | 1998-04-14 | Enzon, Inc. | Interferon polymer conjugates and process for preparing the same |
| AU697440B2 (en) * | 1994-12-07 | 1998-10-08 | Novozymes A/S | Polypeptide with reduced allergenicity |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| SE9503380D0 (en) * | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| AU730969B2 (en) * | 1995-10-19 | 2001-03-22 | University Of Washington | Discrete-length polyethylene glycols |
| US5702717A (en) * | 1995-10-25 | 1997-12-30 | Macromed, Inc. | Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US5747639A (en) * | 1996-03-06 | 1998-05-05 | Amgen Boulder Inc. | Use of hydrophobic interaction chromatography to purify polyethylene glycols |
| JP2001508783A (en) | 1997-01-29 | 2001-07-03 | ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー | PEGylation method |
| AU726374B2 (en) | 1997-03-05 | 2000-11-02 | University Of Washington | Novel screening methods to identify agents that selectively inhibit hepatitis C virus replication |
| US5990237A (en) * | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
| US7642323B2 (en) * | 1997-11-06 | 2010-01-05 | Nektar Therapeutics | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
| US6448369B1 (en) * | 1997-11-06 | 2002-09-10 | Shearwater Corporation | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
| JP4465109B2 (en) * | 1997-12-17 | 2010-05-19 | エンゾン ファーマシューティカルズ，インコーポレーテッド | Polymer prodrugs of amino and hydroxyl containing bioactive agents |
| US6180095B1 (en) * | 1997-12-17 | 2001-01-30 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
| US5981709A (en) | 1997-12-19 | 1999-11-09 | Enzon, Inc. | α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same |
| US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
| US5965119A (en) * | 1997-12-30 | 1999-10-12 | Enzon, Inc. | Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents |
| US6362254B2 (en) * | 1998-03-12 | 2002-03-26 | Shearwater Corporation | Poly(ethylene glycol) derivatives with proximal reactive groups |
| TR200101751T2 (en) | 1998-04-28 | 2002-05-21 | Applied Research Systems Ars Holding N.V. | Polyol-IFN-beta conjugates |
| US6703381B1 (en) | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
| DK1656952T3 (en) * | 1998-10-16 | 2014-01-20 | Biogen Idec Inc | Polyalkylene glycol conjugates of interferon beta-1A and applications thereof |
| KR100698559B1 (en) * | 1999-06-11 | 2007-03-21 | 넥타르 테라퓨틱스 에이엘, 코포레이션 | Hydrogels derived from chitosan and poly (ethylene glycol) or related polymers |
| WO2001015736A2 (en) | 1999-08-27 | 2001-03-08 | Maxygen Aps | Interferon-beta conjugates |
| US6531122B1 (en) * | 1999-08-27 | 2003-03-11 | Maxygen Aps | Interferon-β variants and conjugates |
| US7144574B2 (en) * | 1999-08-27 | 2006-12-05 | Maxygen Aps | Interferon β variants and conjugates |
| DE60026073T2 (en) | 1999-12-22 | 2006-09-28 | Nektar Therapeutics Al, Corp., Huntsville | STERRICOUS DERIVATIVES OF WATER-SOLUBLE POLYMERS |
| US6413507B1 (en) * | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
| ATE516820T1 (en) * | 2000-09-29 | 2011-08-15 | Schering Corp | PEGYLATED INTERLEUKIN 10 |
| US7053150B2 (en) * | 2000-12-18 | 2006-05-30 | Nektar Therapeutics Al, Corporation | Segmented polymers and their conjugates |
| TW593427B (en) * | 2000-12-18 | 2004-06-21 | Nektar Therapeutics Al Corp | Synthesis of high molecular weight non-peptidic polymer derivatives |
| TR200301208T2 (en) * | 2001-02-01 | 2005-05-23 | Biogen, Inc. | Nublastin polymer conjugates and methods of using them. |
| PL367154A1 (en) | 2001-02-27 | 2005-02-21 | Maxygen Aps | New interferon beta-like molecules |
| US7009033B2 (en) * | 2001-07-02 | 2006-03-07 | Polymer Source Inc. | Heterofunctional polyethylene glycol and polyethylene oxide, process for their manufacture |
| EP2236161A1 (en) * | 2001-10-18 | 2010-10-06 | Nektar Therapeutics | Polymer conjugates of opioid antagonists |
| EA008505B1 (en) * | 2001-11-20 | 2007-06-29 | Фармация Корпорейшн | Chemically modified human growth hormone conjugates |
| EP1507755A4 (en) * | 2001-12-11 | 2006-05-17 | Sun Bio Inc | Novel monofunctional polyethylene glycol aldehydes |
| US6916962B2 (en) | 2001-12-11 | 2005-07-12 | Sun Bio, Inc. | Monofunctional polyethylene glycol aldehydes |
| US6956135B2 (en) * | 2001-12-11 | 2005-10-18 | Sun Bio, Inc. | Monofunctional polyethylene glycol aldehydes |
| KR100488351B1 (en) * | 2001-12-11 | 2005-05-11 | 선바이오(주) | Novel polyethylene glycol-propionaldehyde derivatives |
| US7041855B2 (en) * | 2001-12-11 | 2006-05-09 | Sun Bio, Inc. | Monofunctional polyethylene glycol aldehydes |
| DK3025726T3 (en) * | 2002-01-18 | 2019-12-09 | Biogen Ma Inc | POLYALKYLENE POLYMER COMPOUNDS AND APPLICATIONS THEREOF |
| KR100974843B1 (en) * | 2002-09-09 | 2010-08-11 | 넥타르 테라퓨틱스 | Water Soluble Polymer Alkanal |
| CN102319437B (en) * | 2002-12-26 | 2017-10-13 | 山景医药公司 | Polymer conjugates of interferon-beta with enhanced biological utility |
| US20110165122A1 (en) * | 2009-11-10 | 2011-07-07 | The Regents Of The University Of California | Method for targeted and sustained antiviral therapy |
-
2003
- 2003-01-17 DK DK15203017T patent/DK3025726T3/en active
- 2003-01-17 DK DK03731987.8T patent/DK1476181T3/en active
- 2003-01-17 CZ CZ2004877A patent/CZ2004877A3/en unknown
- 2003-01-17 KR KR1020047011171A patent/KR100964411B1/en not_active Expired - Lifetime
- 2003-01-17 WO PCT/US2003/001559 patent/WO2003061577A2/en not_active Ceased
- 2003-01-17 CA CA2473526A patent/CA2473526C/en not_active Expired - Lifetime
- 2003-01-17 EP EP03731987.8A patent/EP1476181B1/en not_active Expired - Lifetime
- 2003-01-17 EE EEP200400105A patent/EE05509B1/en unknown
- 2003-01-17 CA CA2753899A patent/CA2753899C/en not_active Expired - Lifetime
- 2003-01-17 SI SI200332472A patent/SI1476181T1/en unknown
- 2003-01-17 NZ NZ534708A patent/NZ534708A/en not_active IP Right Cessation
- 2003-01-17 UA UA20040706173A patent/UA82184C2/en unknown
- 2003-01-17 BR BRPI0306993A patent/BRPI0306993B8/en not_active IP Right Cessation
- 2003-01-17 HU HUE15203017A patent/HUE047557T2/en unknown
- 2003-01-17 CA CA2840490A patent/CA2840490C/en not_active Expired - Lifetime
- 2003-01-17 GE GEAP8365A patent/GEP20064024B/en unknown
- 2003-01-17 EP EP19203313.2A patent/EP3669887A1/en not_active Withdrawn
- 2003-01-17 ME MEP-2008-356A patent/ME00239B/en unknown
- 2003-01-17 MX MXPA04006855A patent/MXPA04006855A/en active IP Right Grant
- 2003-01-17 ME MEP-356/08A patent/MEP35608A/en unknown
- 2003-01-17 JP JP2003561523A patent/JP2005526151A/en active Pending
- 2003-01-17 EA EA200400962A patent/EA009783B1/en active Protection Beyond IP Right Term
- 2003-01-17 GE GEAP20038365A patent/GEP20074024B/en unknown
- 2003-01-17 SK SK310-2004A patent/SK3102004A3/en not_active Application Discontinuation
- 2003-01-17 PL PL372728A patent/PL213322B1/en unknown
- 2003-01-17 HU HU0500457A patent/HU230473B1/en unknown
- 2003-01-17 ES ES15203017T patent/ES2774801T3/en not_active Expired - Lifetime
- 2003-01-17 PL PL397261A patent/PL397261A1/en unknown
- 2003-01-17 AU AU2003210564A patent/AU2003210564B2/en active Active
- 2003-01-17 SI SI200332604T patent/SI3025726T1/en unknown
- 2003-01-17 ES ES03731987.8T patent/ES2566797T3/en not_active Expired - Lifetime
- 2003-01-17 CA CA2952488A patent/CA2952488C/en not_active Expired - Lifetime
- 2003-01-17 CN CN2009102081892A patent/CN101700401B/en not_active Expired - Lifetime
- 2003-01-17 RS YU63504A patent/RS55578B1/en unknown
- 2003-01-17 EP EP15203017.7A patent/EP3025726B1/en not_active Expired - Lifetime
- 2003-01-17 EA EA200701386A patent/EA011829B1/en not_active IP Right Cessation
- 2003-01-17 CN CNA038057972A patent/CN1630530A/en active Pending
- 2003-01-17 HU HUE03731987A patent/HUE028163T2/en unknown
- 2003-01-17 PT PT152030177T patent/PT3025726T/en unknown
-
2004
- 2004-07-14 IL IL163006A patent/IL163006A/en active Protection Beyond IP Right Term
- 2004-07-15 IS IS7353A patent/IS2989B/en unknown
- 2004-07-16 US US10/892,830 patent/US8017733B2/en active Active
- 2004-08-10 BG BG108839A patent/BG66525B1/en unknown
- 2004-08-17 ZA ZA2004/06555A patent/ZA200406555B/en unknown
- 2004-08-17 NO NO20043422A patent/NO339857B1/en not_active IP Right Cessation
-
2009
- 2009-04-30 JP JP2009110274A patent/JP5275125B2/en not_active Expired - Lifetime
-
2011
- 2011-09-12 US US13/230,080 patent/US8524660B2/en not_active Expired - Lifetime
-
2012
- 2012-07-05 JP JP2012151745A patent/JP2012255156A/en active Pending
-
2013
- 2013-01-21 JP JP2013008426A patent/JP2013136756A/en not_active Abandoned
-
2015
- 2015-07-02 JP JP2015133310A patent/JP6030717B2/en not_active Expired - Lifetime
- 2015-08-26 NO NO20151082A patent/NO344612B1/en not_active IP Right Cessation
-
2016
- 2016-04-11 CY CY20161100288T patent/CY1117349T1/en unknown
- 2016-08-03 LU LU93162C patent/LU93162I2/en unknown
- 2016-08-04 BE BE2016C040C patent/BE2016C040I2/fr unknown
- 2016-08-05 CY CY2016027C patent/CY2016027I2/en unknown
- 2016-08-11 NL NL300826C patent/NL300826I2/nl unknown
- 2016-08-12 FR FR16C0034C patent/FR16C0034I2/en active Active
- 2016-08-18 HU HUS1600035C patent/HUS1600035I1/en unknown
-
2017
- 2017-04-10 NO NO2017013C patent/NO2017013I2/en unknown
-
2020
- 2020-02-06 CY CY20201100115T patent/CY1122841T1/en unknown
-
2026
- 2026-01-13 NO NO2026002C patent/NO2026002I1/en unknown